Media

  • Home
  • About Us
  • Products + Pipeline
    • About Cenobamate
  • Healthcare Professionals
  • About Epilepsy
  • Careers
  • Media
    • Press Release
    • Events
  • Contact
  • News + Press Releases
  • Events
  • 2021
  • 2020
  • 2019

Arvelle Announces Partnership with Durbin Across Europe

Zug, Switzerland, 17 August 2020 – Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to…

Press Release August 17, 2020

Cenobamate Designated Promising Innovative Medicine (PIM) by the UK’s MHRA for Treatment of Drug-Resistant Focal-Onset Seizures in Adults

PIM designation is an early indication that cenobamate is a promising candidate for the MHRA’s Early Access to Medicine Scheme Milestone further…

Press Release August 11, 2020

Arvelle to Present at Jefferies Virtual 2020 Healthcare Conference

Zug, Switzerland, 1 June 2020 – Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to…

Press Release June 1, 2020

Arvelle Announces Closing of Final Tranche of Series A Financing Round

Brings the total financing to $207.8m Triggered by successful filing and validation of the MAA for cenobamate Zug, Switzerland, 26 May 2020 –…

Press Release May 26, 2020

Results of a Randomised Study Showing that Adjunctive Cenobamate Significantly Improved Seizure control in Adults with Uncontrolled Focal Seizures Published in Neurology 1

28% of patients receiving cenobamate achieved seizure-freedom (zero seizures) during the study’s maintenance phase, versus 9% receiving placebo1…

Press Release May 21, 2020

SK Life Science, Inc. Announces US Availability of XCOPRI® (cenobamate tablets) for the Treatment of Partial (Focal) Onset Seizures in Adults with Epilepsy

Arvelle Therapeutics has exclusive rights to develop and commercialize cenobamate in Europe Zug, Switzerland, 12 May 2020 – Arvelle…

Press Release May 12, 2020

Arvelle Announces European Medicines Agency Acceptance of the Marketing Authorization Application (MAA) for Cenobamate

The MAA seeks authorisation for the adjunctive treatment of focal-onset seizures in adult patients with epilepsy Zug, Switzerland, 26 March 2020…

Press Release March 26, 2020

Related Articles


  • The Lancet Neurology

    November 13, 2019
    Results of Randomized Study Evaluating the Safety and Efficacy of Cenobamate in Patients with Uncontrolled Focal-Onset Epilepsy Published
  • Bioworld

    November 4, 2019
    Arvelle’s CEO Mark Altmeyer Interview
+41 44 5672940 info@arvelletx.com

Arvelle Therapeutics
International GmbH
Zählerweg 6,
6301 Zug, Switzerland

LinkedIn LinkedIn Twitter Twitter
  • Home
  • Privacy Policy